MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study-Reference-Cited by-同舟云学术

MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Published:2021-05 Issue: Volume:424 Page:117385
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

De Mercanti Stefania Federica,Signori Alessio,Cordioli Cinzia,Signoriello Elisabetta,Lus Giacomo,Bonavita Simona,Abbadessa Gianmarco,Lavorgna Luigi,Maniscalco Giorgia Teresa,Curti Erica,Lorefice Lorena,Cocco Eleonora,Nociti Viviana,Mirabella Massimiliano,Baroncini Damiano,Mataluni Giorgia,Landi Doriana,Petruzzo Martina,Lanzillo Roberta,Gandoglia Ilaria,Laroni Alice,Frangiamore Rita,Sartori Arianna,Cavalla Paola,Costantini Gianfranco,Capra Ruggero,Sormani Maria Pia,Clerico Marinella

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference12 articles.

1. Disease-modifying treatments for multiple sclerosis - a review of approved medications;Torkildsen;Eur. J. Neurol.,2016

2. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon Beta-1a for multiple sclerosis;Kleinschmidt-DeMasters;N. Engl. J. Med.,2005

3. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab;Langer-Gould;N. Engl. J. Med.,2005

4. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS;Rudick;Expert. Rev. Neurother.,2004

5. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing;van Kempen;Mult. Scler. J.,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

2. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab;Multiple Sclerosis and Related Disorders;2024-07

3. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches;Immunopharmacology and Immunotoxicology;2024-04-18

4. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience;Neurotherapeutics;2024-04

5. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis;Acta Neurologica Belgica;2024-03-08